论文部分内容阅读
目的:探讨吉西他滨联合重组人血管内皮抑制素YH-16对裸鼠CD133+MHCC97H肝癌移植瘤中肝癌干细胞样细胞的影响。方法:用免疫磁珠分选MHCC97H中肝癌干细胞样细胞,将其接种到20只裸鼠皮下,建立移植瘤模型。治疗组给予吉西他滨和YH-16,对照组给予等量生理盐水,比较两组移植瘤大小变化及原代培养细胞球形成情况,流式细胞术检测原代培养中CD133+细胞百分率。结果:治疗组的移植瘤明显缩小,治疗组和对照组细胞球形成数目分别为(7.5±2.4)个vs(16.0±3.5)个,细胞球直径分别为(178.30±19.21)μmvs(131.06±20.96)μm(P<0.05);治疗组和对照组原代培养中CD133+细胞百分数分别为(6.24±0.96)%vs(18.26±1.76)%(P<0.05)。结论:低剂量吉西他滨联合YH-16可抑制血管内皮细胞破坏肝癌干细胞样细胞的血管巢,进而选择性清除肝癌干细胞样细胞。
Objective: To investigate the effect of gemcitabine combined with recombinant human endostatin YH-16 on hepatoma stem cell-like cells in the transplanted hepatocellular carcinoma of CD133 + MHCC97H in nude mice. METHODS: Hepatoma stem cell-like cells in MHCC97H were sorted by immunomagnetic beads and inoculated into 20 nude mice subcutaneously to establish a transplanted tumor model. Gemcitabine and YH-16 were given to the treatment group, and normal saline was given to the control group. The size of the primary tumor cells and the percentage of CD133 + cells in the primary culture were compared by flow cytometry. Results: The number of tumor cells in treatment group and control group were (7.5 ± 2.4) vs (16.0 ± 3.5), respectively, and the diameter of sphere sphere was (178.30 ± 19.21) μmvs (131.06 ± 20.96 ) μm (P <0.05). The percentages of CD133 + cells in the primary culture and control groups were (6.24 ± 0.96)% vs (18.26 ± 1.76)% (P <0.05), respectively. Conclusion: Low dose of gemcitabine combined with YH-16 can inhibit vascular endothelial cells from destroying the blood vessel nests of hepatoma stem cell-like cells, and then selectively eliminating hepatoma stem cell-like cells.